Phase 4 N=30 Vapocoolant Spray Used Prior to Intravenous (IV) Insertions
Pain
Primary: Pain Scale Using Visual Analog Scale — 1.13; 1.60 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=302 Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
Diabetic Macular Edema
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12 — 6.8; 8.5; 8.8…
Phase 3 N=431 A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
Breast Neoplasms · BRCA 1 Gene Mutation · BRCA 2 Gene Mutation
Primary: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment — 8.6; 5.6 months — p=<0.0001
Phase 3 N=915 A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)
Renal Cell Carcinoma
Primary: Percentage of Participants With Disease Progression as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)…
Phase 3 N=1,250 Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Primary: Number of Subjects Prematurely Discontinuing Due to a Treatment-emergent Adverse Event (TEAE) During the Treatment Period (Maximum 96 Weeks) — 26; 45; 25; 51 Participants
Phase 1 N=26 A Study of Evacetrapib and Rifampin in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Evacetrapib — 599; 269 nanograms per milliliter (ng/mL)
Phase 2 N=63 A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: Percentage Change in Psoriasis Area and Severity Index (PASI) — -5.6; -7.6; -0.3; -12.7 percentage of change in PASI index score — p=0.89
Phase 1 N=39 A Study of LY2484595 in Healthy Subjects
Healthy Volunteers
Primary: Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve (AUC) of LY2484595 — 12200; 17800; 17800 hours times nanograms per milliliter
Phase 3 N=119 A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
Attention Deficit Hyperactivity Disorder
Primary: Swanson, Kotkin, Agler, M-Flynn and Pelham Combined Score (SKAMP CS) - Model-adjusted Average of All Post-dose Time Points Assessed During a Laboratory Classroom Test…
Phase 1 N=24 Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of S-Warfarin — 128; 114 nanogram*hour/milliliter (ng*h/mL)
Phase 1 N=20 A Study of LY2608204 in Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Number of Participants With Clinically Significant Adverse Effects — 9; 8; 9; 8 Participants
Phase 2 N=30 Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse
Opioid Abuse
Primary: Drug Like/Dislike Effect at 30 Minutes Post Dose (E 30 Min) — 11.7; 14.7 score on a scale
Phase 4 N=596 Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc
Hepatitis B · Hepatitis A
Primary: Antibody Concentrations for Anti-hepatitis A Virus (Anti-HAV) and Anti-hepatitis B Surface (Anti-HBs) Antigens — 2746.5; 1153.9 mIU/mL
Phase 3 N=163 A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting
Attention Deficit Hyperactivity Disorder
Primary: Attention Deficit Hyperactivity Disorder Rating Scale Based on DSM-IV Criteria (ADHD-RS-IV) Total Score. — 24.1; 31.2 ADHD-RS-IV total score — p=0.05
Phase 1 N=24 A Study of Evacetrapib in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Evacetrapib — 1270; 1290 nanograms/milliliter (ng/mL)